CA088-1005

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component

What's the purpose of the trial?

The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).
Trial status

Accepting patients

Phase
Phase 1
Enrollment
111
Last Updated
2 weeks ago
Patient Screener

Participating Centers

There are 17 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • BMS-986393 (CC-95266) is an investigational study medicine that belongs to a type of immunotherapy known as chimeric antigen receptor T-cell (CAR-T) therapy. This type of therapy involves T-cells being taken from the patient and being modified to be able to recognize myeloma tumor cells more easily.
  • Iberdomide is a Cereblon (CRBN) binding compound currently under clinical investigation for multiple myeloma.
  • Mezigdomide is a Cereblon (CRBN) binding compound currently under clinical investigation for multiple myeloma.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Part 1: BMS-986393 + Mezigdomide

Accepting patients

Part 1: BMS-986393 + Iberdomide

Not yet accepting

Part 2: BMS-986393 + Mezigdomide

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.